Wockhardt Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Wockhardt Ltd fell for a fifth straight session today. The stock is quoting at Rs 1874, down 0.72% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.67% on the day, quoting at 23396.85. The Sensex is at 74514.44, up 0.81%.Wockhardt Ltd has gained around 15.28% in last one month.Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has increased around 0.8% in last one month and is currently quoting at 24290.3, up 0.3% on the day. The volume in the stock stood at 8.81 lakh shares today, compared to the daily average of 32.74 lakh shares in last one month.

The PE of the stock is 105.01 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Sky Gold & Diamonds Ltd, Hindustan Zinc Ltd, HFCL Ltd and National Aluminium Company Ltd are among the other losers in the BSE's 'A' group today, 05 June 2026.

Wockhardt Ltd tumbled 7.09% to Rs 1926 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 2.4 lakh shares were traded on the counter so far as against the average daily volumes of 1.96 lakh shares in the past one month.

Sky Gold & Diamonds Ltd crashed 6.92% to Rs 531.8. The stock was the second biggest loser in 'A' group.On the BSE, 1.28 lakh shares were traded on the counter so far as against the average daily volumes of 1.38 lakh shares in the past one month.

Hindustan Zinc Ltd lost 5.87% to Rs 568.3. The stock was the third biggest loser in 'A' group.On the BSE, 3.36 lakh shares were traded on the counter so far as against the average daily volumes of 2.91 lakh shares in the past one month.

HFCL Ltd fell 5.00% to Rs 187.2. The stock was the fourth biggest loser in 'A' group.On the BSE, 24.55 lakh shares were traded on the counter so far as against the average daily volumes of 34.53 lakh shares in the past one month.

National Aluminium Company Ltd pared 4.90% to Rs 393.65. The stock was the fifth biggest loser in 'A' group.On the BSE, 3.74 lakh shares were traded on the counter so far as against the average daily volumes of 4.44 lakh shares in the past one month.

Powered by Capital Market - Live News

The stock had surged 36.60% over the previous five trading sessions after the company announced that the U.S. Food and Drug Administration had approved ZAYNICH for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis.

Investor sentiment has remained buoyant following the regulatory milestone. The stock gained 15.50% over the past week, advanced 41.12% in the last month and is up 38.42% so far in 2026.

The approval comes days after ZAYNICH received marketing approval in India on 27 May 2026. Wockhardt said the drug is the first new chemical entity fully discovered, developed and commercialised by an Indian pharmaceutical company to secure approval from the U.S. FDA.

ZAYNICH combines cefepime, a fourth-generation cephalosporin antibiotic, with zidebactam, a novel beta-lactam enhancer. The therapy is designed to combat multidrug-resistant Gram-negative bacteria, including strains resistant to many existing antibiotics.

The FDA's decision was supported by data from the global Phase 3 ENHANCE-1 trial involving 530 patients across 64 sites worldwide. According to the company, ZAYNICH achieved a combined clinical cure and microbiological response rate of 89% at the test-of-cure visit, compared with 68.4% for meropenem.

The drug has also been granted Qualified Infectious Disease Product (QIDP), Fast Track and Priority Review designations by the U.S. regulator. Wockhardt has additionally submitted a marketing authorisation application for the product to the European Medicines Agency.

Wockhardt is a research-driven pharmaceutical and biotechnology company focused on anti-infective therapies. The company currently has six antibiotics at various stages of development and commercialisation, all of which have received QIDP designation from the U.S. FDA.

For the quarter ended March 2026, Wockhardt reported a consolidated net profit of Rs 164 crore, compared with a net loss of Rs 45 crore in the corresponding period last year. Revenue from operations rose 29.87% YoY to Rs 965 crore.

Powered by Capital Market - Live News

Wockhardt Ltd is up for a fifth straight session today. The stock is quoting at Rs 2201.1, up 8.35% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.14% on the day, quoting at 23515.85. The Sensex is at 74689.48, down 0.12%. Wockhardt Ltd has gained around 54.46% in last one month.

Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has gained around 3.41% in last one month and is currently quoting at 24345.8, down 0.28% on the day. The volume in the stock stood at 84.82 lakh shares today, compared to the daily average of 40.05 lakh shares in last one month.

The PE of the stock is 113.01 based on TTM earnings ending March 26.

Powered by Capital Market - Live News